The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
India business is growing as per projections; whereas US business will bounce back soon.
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Subscribe To Our Newsletter & Stay Updated
